Predict your next investment

Private Equity
genechem.com

See what CB Insights has to offer

Investments

42

Portfolio Exits

17

About GeneChem Management

GeneChem Management Inc. is a Montreal, Canada-based stage agnostic private equity and venture capital firm that engages in everything from seed and startup financings to later stage mezzanine rounds to PIPE (private placements in public equities) investments. GeneChem customarily invests in the genomics industries with a focus on companies involved in gene discovery, functional genomics, bioinformatics, proteomics, and gene therapy amongst other related areas. Geographically, GeneChem seeks to invest in Canada, the United States, and Europe and generally prefers to have a Board seat and be the lead investor. In early stage deals, GeneChem may be the sole investor but it generally prefers to be part of syndicated deals as a lead or follower.

GeneChem Management Headquarter Location

1001 De Maisonneuve Blvd, West Suite 920

Montreal, Quebec, H3A 3C8,

Canada

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest GeneChem Management News

Investor Profile: Burrill & Company

Aug 17, 2013

Apple Giovanni Ferrara from Burrill & Company is a member of FundingPost online! Venture Fund Member Profile Share This Profile: Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses) with over $500 million under management. Burrill's technical and venture investing competence spans the entire spectrum of life sciences. The expertise of the firm's investment team, strategic partners and Advisory Boards is unparalleled in depth and breadth. In addition, Burrill is a leader in life science strategic partnering, an invaluable practice to build value in portfolio companies and to accelerate their growth and development. Giovanni Ferrara Managing Director Burrill & Company Prior to joining Burrill & Company, Mr. Ferrara was Manager at GeneChem Management, Inc., a healthcare venture capital firm, where he led several syndicated investments in Canada and the United States. He also held interim operating positions in portfolio companies and worked closely with BioChem Pharma's CSO and business development team in sourcing and pursuing inlicensing opportunities, which led to two of BioChem's largest deals, having achieved approximately $95 million in business development transactions. Prior to joining the venture capital community, he was a financial analyst at Letko, Brosseau & Associates. He began his career in healthcare as a pharmacist at a private cancer treatment center in Toronto focusing on experimental therapies. Representative Investments Adlyfe is a company that is developing screening and diagnostic products based upon its misfolded-protein detection (MPD) platform. The Company is developing its MPD Platform technology to produce simple, highly sensitive, low-cost and rapid-action test kits for the blood screening, human diagnostics and animal testing markets. The Company is currently working on the following programs: TSE-Pronucleon, to enable rapid and accurate testing of human blood units for vCJD and AD-Pronucleon an MPD Platform-based assay for early diagnosis of Alzheimer’s disease (AD). CardioKine develops pharmaceuticals for the treatment and prevention of heart failure and related cardiovascular indications. Their initial product, Lixivaptan, an electrolyte-sparing diuretic, was licensed from Wyeth. Corazonas offers snacks that are formulated using ingredients that are scientifically proven to help maintain heart health. The first offering in the Corazonas platform is heart healthy tortilla chips, formulated using whole oats and plant sterols, with no trans fats, reduced sodium and virtually no saturated fat. Dreamerz has developed an all natural sleep aid beverage. Dreamerz beverage contains based product targeted to the quality of sleep market. About FundingPost For over Fourteen Years FundingPost has worked with thousandsof Angel and Venture Capital Investors. We believe that it isimportant to reach investors in every medium possible -both online and offline. We have been directly responsible fortons of success stories and Millions and Millions of dollars raised.We look forward to introducing your company to the leading Venture and Angel Investors nationwide. Sign up now: Entrepreneurs / Investors Join the FundingPost email list and learn how, when and where you can meet these Investors: Other Venture Profiles:

GeneChem Management Investments

42 Investments

GeneChem Management has made 42 investments. Their latest investment was in NuChem Therapeutics as part of their Unattributed VC on December 12, 2011.

CBI Logo

GeneChem Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/4/2011

Unattributed VC

NuChem Therapeutics

Yes

2

6/21/2011

Series D - II

Ambit Biosciences

$30M

No

4/19/2010

Series A - II

Sonexa Therapeutics

$7.23M

No

5/21/2009

Unattributed

Subscribe to see more

$99M

Subscribe to see more

0

5/8/2008

Series A

Subscribe to see more

$99M

Subscribe to see more

0

Date

12/4/2011

6/21/2011

4/19/2010

5/21/2009

5/8/2008

Round

Unattributed VC

Series D - II

Series A - II

Unattributed

Series A

Company

NuChem Therapeutics

Ambit Biosciences

Sonexa Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$30M

$7.23M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

0

0

GeneChem Management Portfolio Exits

17 Portfolio Exits

GeneChem Management has 17 portfolio exits. Their latest portfolio exit was NuChem Therapeutics on February 22, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/22/2019

Management Buyout

Management Buyout (MBO)

1

7/15/2013

Reverse Merger

1

5/16/2013

IPO

$99M

2

1/10/2013

Acquired

Subscribe to see more

Subscribe to see more

10

1/25/2011

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/22/2019

7/15/2013

5/16/2013

1/10/2013

1/25/2011

Exit

Management Buyout

Reverse Merger

IPO

Acquired

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Management Buyout (MBO)

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

GeneChem Management Team

1 Team Member

GeneChem Management has 1 team member, including current President, Louis P. Lacasse.

Name

Work History

Title

Status

Louis P. Lacasse

President

Current

Name

Louis P. Lacasse

Work History

Title

President

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.